Biogen's EBIT per Share for the
three
months ended in Dec. 2023 was $2.49.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.61.
During the past 12 months, the average EBIT per Share Growth Rate of Biogen was -36.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -23.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -17.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 1.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Biogen's EBIT per Share or its related term are showing as below:
BIIB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -71 Med: 20.3 Max: 234.6
Current: -23
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biogen was 234.60% per year. The lowest was -71.00% per year. And the median was 20.30% per year.
BIIB's 3-Year EBIT Growth Rate is ranked worse than 84.41% of 853
companies
in the Drug Manufacturers industry
Industry Median: 7.7
vs BIIB: -23.00
Biogen's EBIT for the
three
months ended in Dec. 2023 was $363 Mil.
Biogen EBIT per Share Historical Data
The historical data trend for Biogen's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biogen Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EBIT per Share
39.03
32.67
13.36
26.29
10.60
Biogen Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EBIT per Share
4.53
3.45
5.20
-0.54
2.49
Biogen EBIT per Share Calculation
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Biogen's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (NAS:BIIB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Biogen EBIT per Share Related Terms
Thank you for viewing the detailed overview of Biogen's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIIB has been successfully added to your 